Literature DB >> 31954893

Insulin in the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Christian D Cerecedo-Lopez1, Alejandra Cantu-Aldana2, Nirav J Patel1, M Ali Aziz-Sultan1, Kai U Frerichs1, Rose Du3.   

Abstract

OBJECTIVE: The role of tight glycemic control in the management of acute ischemic stroke remains uncertain. Our goal is to evaluate the effects of tight glucose control with insulin therapy after acute ischemic stroke.
METHODS: We searched PubMed, CENTRAL, and Embase for randomized controlled trials (RCTs) that evaluated the effects of tight glycemic control (70-135 mg/dL) in acute ischemic stroke. Analysis was performed using fixed-effects and random-effects models. Outcomes were death, independence, and modified Rankin Scale (mRS) score at ≥90 days follow-up, and symptomatic or severe hypoglycemia during treatment.
RESULTS: Twelve RCTs including 2734 patients were included. Compared with conventional therapy or placebo, tight glycemic control was associated with similar rates of mortality at ≥90 days follow-up (pooled odds ratio [pOR], 0.99; 95% confidence interval [CI], 0.79-1.22]; I2 = 0%), independence at ≥90 days follow-up (pOR, 0.95; 95% CI, 0.79-1.14; I2 = 0%) and mRS scores at ≥90 days follow-up (standardized mean difference, 0.014; 95% CI, -0.15 to 0.17; I2 = 0%). In contrast, tight glycemic control was associated with increased rates of symptomatic or severe hypoglycemia during treatment (pOR, 5.2; 95% CI, 1.7-15.9; I2 = 28%).
CONCLUSIONS: Tight glucose control after acute ischemic stroke is not associated with improvements in mortality, independence, or mRS score and leads to higher rates of symptomatic or severe hypoglycemia.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glucose; Hyperglycemia; Insulin; Meta-analysis; Stroke

Year:  2020        PMID: 31954893     DOI: 10.1016/j.wneu.2020.01.056

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Continuous Intravenous versus Subcutaneous Administration of Insulin for Glycemic Variability in Acute Ischemic Stroke.

Authors:  Lin-Zhe Du; Pei-Yan Liu; Chen-Yan Ge; Yang Li; Yuan-Yuan Li; Mu-Fei Tang; Jin-Jin Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-01       Impact factor: 2.989

2.  Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke.

Authors:  Gregory Y H Lip; Deirdre A Lane; Radosław Lenarczyk; Giuseppe Boriani; Wolfram Doehner; Laura A Benjamin; Marc Fisher; Deborah Lowe; Ralph L Sacco; Renate Schnabel; Caroline Watkins; George Ntaios; Tatjana Potpara
Journal:  Eur Heart J       Date:  2022-07-07       Impact factor: 35.855

3.  Effects of β-Adrenergic Blockade on Metabolic and Inflammatory Responses in a Rat Model of Ischemic Stroke.

Authors:  Shih-Yi Lin; Ya-Yu Wang; Cheng-Yi Chang; Chih-Cheng Wu; Wen-Ying Chen; Yu-Hsiang Kuan; Su-Lan Liao; Chun-Jung Chen
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

4.  Biodistribution of Insulin Following Massive Insulin Subcutaneous Injection.

Authors:  Tomoya Ikeda; Naoto Tani; Tatsuya Hirokawa; Kei Ikeda; Fumiya Morioka; Alissa Shida; Yayoi Aoki; Takaki Ishikawa
Journal:  Intern Med       Date:  2022-03-12       Impact factor: 1.282

5.  A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care.

Authors:  Sung-Chun Tang; Shyang-Rong Shih; Shin-Yi Lin; Chih-Hao Chen; Shin-Joe Yeh; Li-Kai Tsai; Wei-Shiung Yang; Jiann-Shing Jeng
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.